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Abstract
Background: A circadian rhythm of symptoms has been reported in allergic rhinitis and some
studies have shown the dosing time of antihistamines to be of importance for optimizing symptom
relief in this disease. The objective of this study was to examine the efficacy of morning vs. evening
dosing of the antihistamine desloratadine at different time points during the day.
Methods: Patients ≥ 18 years, with seasonal allergic rhinitis received desloratadine 5 mg orally
once daily in the morning (AM-group) or evening (PM-group) for two weeks. Rhinorrhea, nasal
congestion, sneezing and eye symptoms were scored morning and evening. Wilcoxon rank sum and
2-way ANOVA test were used.
Results: Six-hundred and sixty-three patients were randomized; 336 in the AM-group; 327 in the
PM-group. No statistically significant differences were seen between the AM and PM group at any
time points. In the sub-groups with higher morning or evening total symptom score no difference
in treatment efficacy was seen whether the dose was taken 12 or 24 hours before the higher score
time. There was a circadian variation in baseline total symptom score; highest during daytime and
lowest at night. The circadian variation in symptoms was reduced during treatment. This reduction
was highest for daytime symptoms.
Conclusions: A circadian rhythm was seen for most symptoms being more pronounced during
daytime. This was less apparent after treatment with desloratadine. No statistically significant
difference in efficacy was seen whether desloratadine was given in the morning or in the evening.
This gives the patients more flexibility in choosing dosing time.
Background
Allergic rhinitis is a common illness, which affects approx-
imately 15 % of the population [1] and has a large impact
on the quality of life of the patients. In some studies the
symptoms of allergic rhinitis have shown a circadian
rhythm with morning symptoms being most prominent
in a majority of patients [1-6].
Antihistamines are important medications in the treat-
ment of allergic rhinitis. One should expect that the effect
of an antihistamine is best near or shortly after peak
serum level is attained. If this also coincides with the peak
in allergy symptoms, an optimal treatment effect should
be expected. In one study evening dosing of the antihista-
mine mequitazine (half-life of 38–45 hours and time to
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peak serum level about 6 hours) gave better symptom
relief than morning dosing on morning symptoms [4,7].
Desloratadine has as mequitazine a rather long half life of
27 hours, and the time to peak serum level at about 3
hours [8]. Evening dosing of this antihistamine may be
expected to give better symptom relief than morning dos-
ing on peak morning symptoms. Some studies have also
confirmed a circadian variation in efficacy of some anti-
histamines on histamine induced skin reactions [9,10].
The aim of this study was to examine the efficacy of the
antihistamine desloratadine at different time points dur-
ing the day and to evaluate whether the time of dosing of
desloratadine has any impact on the treatment efficacy in
seasonal allergic rhinitis (SAR).
Methods
This was a randomized, open label, parallel group, multi-
center study of two weeks duration in patients with SAR
during the birch or grass pollen season. Eighty one medi-
cal centers in the Nordic countries participated. The inclu-
sion criteria were: patients 18 years or above with a
minimum of two years history of SAR confirmed by either
a positive skin prick test or a positive serologic allergen
test to the relevant seasonal allergen; clinically sympto-
matic with SAR at baseline/inclusion with a minimum
total nasal symptom score (rhinorrhea, congestion, itch-
ing and sneezing) of at least 6 and rhinorrhea being min-
imum 2 (moderate); willingness to adhere to dosing and
visit schedule. Females of childbearing potential had to
use medically accepted methods of birth control and writ-
ten informed consent had to be obtained from all
patients.
The exclusion criteria were: pulmonary disease, perennial
rhinitis, sinusitis, rhinitis medicamentosa, pollen desensi-
tization during the last 6 months, respiratory tract infec-
tion within the last two weeks, structural nasal
abnormalities (including polyps), use of oral, nasal, ocu-
lar decongestants, corticosteroids in any form (except
mild dermatological group I corticosteroids allowed in
only small areas), other antihistamines (oral or topical),
any investigational drug during the last 30 days, pregnant
or nursing females.
The patients were randomized into one of two treatment
groups with dosing of 5 mg desloratadine tablets either in
the morning between 07 – 09 (AM-group) or evening
between 19 – 21 (PM-group) in a 1:1 ratio. Randomizing
was computer generated for the whole study population
using SAS version 6.12 and performed in blocks of eight.
Each subject unit (bottle with medication) was labelled
with randomization number. Physicians in the different
Nordic countries recruited the patients. They assigned the
medication in consecutive order. The study was moni-
tored by Schering-Plough.
The following symptoms were assessed using a scale from
0 to 3 (0=none, 1=mild, 2=moderate, 3=severe): rhinor-
rhea, nasal congestion, sneezing, itching nose and eye
symptoms (itching, burning, tearing, redness). These
symptoms were recorded in a patient diary every morning
(AM 12 hours reflective and AM last hour) and evening
(PM 12 hours reflective and PM last hour) both at base-
line and during the 2 weeks treatment period. Interference
with sleep and interference with daily activity were also
assessed by the patients every day using the same scale
from 0 to 3. In addition, the number of hours spent out-
doors was recorded.
Visit 1 was at day 0 at the start of baseline, visit 2 after one
week and visit 3 after two weeks. A wash-out period prior
to Visit 1 was necessary if the patient had been on any
drugs which could interfere with the study results (e.g. no
other commonly used antihistamines allowed during the
prior 10 days). Baseline symptoms were recorded in the
evening at day 0 and the following morning (day 1) after
which the patients started taking the study medication as
randomized. A physical examination was performed at
visit 1 and 3. All adverse events were recorded. The study
period was from April 11th 2001 to September 2nd 2002.
Pollen counts were not recorded.
The primary objective was to evaluate the efficacy of 5 mg
desloratadine taken orally once daily in the morning ver-
sus evening. The primary efficacy variable was the mean
change from baseline for the AM last hour Total Symptom
Score (TSS) over the 2 weeks treatment period. TSS is the
sum of the individual symptom scores for the following
symptoms that in prior studies [2,3] have shown a circa-
dian rhythm: rhinorrhea, nasal stuffiness/congestion,
sneezing and eye symptoms (maximum score 12). Since
nasal itching had shown little circadian rhythm in these
studies, this symptom was omitted from the TSS. AM last
hour was chosen as primary time point since the symp-
toms had in the same studies shown to be worst in the
morning. The study was designed to enrol 700 patients in
order to have 600 evaluable patients. This sample size was
chosen to detect with 90 % power and 5 % significance
level, a difference between treatment groups of 0.6 units
or more in mean change from baseline diary TSS, assum-
ing a pooled SD of 2.25 units.
In a study on morning vs. evening dosing of the antihista-
mine mequitazine the differences in dosing-time-related
efficacy increased in the sub-group of patients having pre-
dominantly morning symptoms [4]. A sub-group analysis
was therefore performed on patients with a higher TSS (≥
1 point difference at baseline) in the morning (AM lastClinical and Molecular Allergy 2005, 3:3 http://www.clinicalmolecularallergy.com/content/3/1/3
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hour) than in the evening (PM last hour) and patients
with higher TSS in the evening than in the morning in this
study. A comparison was then done on the treatment effi-
cacy seen 12 hours and 24 hours after dosing (AM vs. PM
dosing) in these patients.
All patients receiving at least one dose of study drug and
having at least one post dose registration were included in
the efficacy analysis (intention-to-treat, ITT), and con-
firmatory analysis were based on evaluable patients with
no protocol violations. Statistical analyses were made
with 2-way ANOVA. For evaluation of response of therapy
Wilcoxon rank sum test was used. Adverse events were
tabulated.
The study protocol and the patient informed consent
form were approved by Ethics Committees and Health
Authorities in each of the participating countries.
Results
Patients
Six hundred and sixty-three patients were randomized at
baseline; 336 to the AM-group and 327 to the PM-group.
The two groups were comparable with respect to demo-
graphics and baseline characteristics (Tab 1). To assess the
primary parameter 310 in the AM and 294 in the PM
group fulfilled the criteria for ITT. Of the AM group 259
and of the PM group 254 patients completed the study
without any violation. Mean baseline TSS varied between
4.64 and 6.10, a difference of 31%; highest during day-
time (PM 12 hours reflective) and lowest at night (AM 12
hours reflective). The circadian variation at baseline was
more evident for sneezing (around 60% difference
between night and day), rhinorrhea and eye symptoms,
less so for nasal itching and hardly noticeable for nasal
congestion. Fig. 1 shows total and individual symptom
scores at baseline and during two weeks treatment. The
circadian variation was much less apparent during treat-
ment with desloratadine (Fig. 1).
Efficacy
During the two weeks period the mean reduction in TSS ±
SE for AM last hour (primary efficacy variable) was 1.63 ±
0.17 (30 %) for the AM-group and 1.80 ± 0.17 (35 %) for
the PM-group. There was no statistically significant differ-
ence (ITT-analysis) between the groups at this time point
(p = 0.456) or at any other time points. The reduction in
TSS was highest (2.5 – 41%) for day time symptoms (PM
previous 12 hours) and lowest at night. This was evident
for all individual symptoms except for nasal congestion.
In the subgroup analysis comparing TSS AM last hour and
PM last hour at baseline, 32 % of the patients had more
severe symptoms in the morning (≥ 1 point difference in
TSS) than in the evening, and 37 % had more severe
symptoms in the evening. Looking at these two sub-
groups, no difference in treatment efficacy on TSS was
seen 12 or 24 hours post dosing (Fig. 2).
According to their diaries the patients spent in average
more than 3.5 hours outdoors daily. The score for the
interference of SAR on the patients' sleep and daily activity
at baseline and throughout the study is shown in Fig. 3.
Safety
The incidence of treatment related adverse events were
comparable between the groups, 20 % in the AM-group
and 18 % in the PM-group, headache being most fre-
quent, 7 % and 4 % respectively.
Discussion
This study was randomized but without a placebo control.
Since this study was a comparison between two different
dosing times of the same medication, a placebo control
Symptom scores Figure 1
Symptom scores. Total and individual symptom scores at 
baseline and over two weeks treatment period Baseline: ❍  
AM-group; ∆ PM-group, Treatment: ●  AM-group; ▲  PM-
group 1 Max score = 12, 2 Max score = 3Clinical and Molecular Allergy 2005, 3:3 http://www.clinicalmolecularallergy.com/content/3/1/3
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was superfluous. The study was not blinded as there is no
reason to believe that neither the patients nor the physi-
cians should have a biased opinion as to the time of dos-
ing. To blind such a study, the patients need to take study
medication from different boxes in the morning and
evening. However, this method was not used since this
may complicate the study and impair patient compliance.
A circadian rhythm has been found in many diseases, also
in allergic rhinitis [1-6]. The effect of an antihistamine
may be modulated [9-13] by variations in allergen expo-
sure, hormonal activity, organ sensitivity and plasma con-
centration of the drug. In this study we have shown that
desloratadine maintains its effect at different time points
throughout the day and thus the effect appears unaffected
by a modulating factor.
The baseline period in this study lasted 24 hours which is
the same as in the study on mequitazine [4] and other
studies [16,17]. In some studies of the effect of antihista-
mines the baseline period has been longer [14,15]. It
would have been difficult to keep patients in the Nordic
countries off medication for more than one day in addi-
tion to any washout period during the pollen season. We
do not believe that the duration of baseline influenced the
results of this comparative study.
The circadian rhythm at baseline found in this study with
maximum symptoms during the day differs from some
other studies [1-6] where more patients had the most
severe symptoms in the morning. This difference may
partly be due to patient selection. Patients with perennial
rhinitis were excluded from our study. Thus indoor aller-
gens do not influence symptom variation. The patients
spent several hours outdoors during the day in the pollen
season. It seems likely that this exposure would influence
the symptoms. The circadian variation was not apparent
during treatment, possibly because the suppression of
symptoms by desloratadine is more observable when
symptoms are most prominent.
The best effect of mequitazine was obtained after evening
dosing (12 hours before peak of symptoms) compared to
morning dosing (24 hours before peak of symptoms). In
our study no difference in treatment efficacy was seen 12
or 24 hours after dosing in the sub-group analysis of
patients with higher baseline morning or evening TSS.
Whatever the cause for this discrepancy between these two
antihistamines, other antihistamines may show a varia-
tion in effect during the day not only on dermal symp-
toms [9,12] but also on nasal ones. Thus studies on the
effect of other antihistamines in allergic rhinitis should be
encouraged.
The adverse events recorded were of a magnitude and
nature as seen in other studies of desloratadine and other
antihistamines [14-17].
Many patients have circadian variations in symptoms. The
peak of symptoms can be at different time points from
patient to patient. Individual dosing time of medication
may improve symptom relief. Desloratadine, however,
apparently shows no circadian variation in effect.
Sub-group Total Symptom Score Figure 2
Sub-group Total Symptom Score. These sub-groups 
consists of patients with higher (one or more score points) 
morning TSS (AM last hour) than evening TSS (PM last hour) 
at baseline and of patients with higher evening TSS (PM last 
hour) than morning TSS (AM last hour) at baseline. There 
was no statistical significant difference in the treatment effi-
cacy between the AM-group and the PM-group.
Sleep and daily activity Figure 3
Sleep and daily activity. The score for interference with 
sleep and daily activity at baseline and during treatment 
shows that there is a higher interference with daily activity at 
baseline and during treatment than with sleep.Clinical and Molecular Allergy 2005, 3:3 http://www.clinicalmolecularallergy.com/content/3/1/3
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Conclusions
A circadian rhythm was seen for most SAR symptoms at
baseline, being most distressing during daytime, possibly
due to long outdoor exposure. This circadian variation is
less apparent after treatment with desloratadine. No statis-
tically significant difference in efficacy was seen whether
desloratadine was given in the morning or in the evening.
This gives the patients more flexibility in choosing dosing
time.
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